Interv Akut Kardiol. 2004;3(2):67-69
TIROFIBAN ADMINISTRATION BEFORE TRANSPORT TO DIRECT ANGIOPLASTY
- 1 Interní oddělení, Nemocnice Ústí nad Orlicí
- 2 Kardio-Troll, pracoviště invazivní kardiologie, Krajská nemocnice, Pardubice
- 3 Kardiologické oddělení Krajské nemocnice Pardubice
- 4 Interní oddělení, Nemocnice Havlíčkův Brod
- 5 Interní oddělení, Nemocnice Svitavy
In a retrospective 9-month study, we evaluated angiographic parameters in patients treated with tirofiban before transport to direct PCI (group A, 24 patients) and in patients with standard treatment with aspirin and heparin alone (group B, 210 patients). Both groups were comparable in age, gender, presence of diabetes mellitus and previous myocardial infarction. Time from onset of chest pain to direct angioplasty was not different (4.4 hrs vs. 4.3 hrs, P=NS). There was no significant difference in TIMI flow before direct angioplasty (TIMI 0 66.7 % vs. 70.5 %, P=NS) nor after this procedure (TIMI 3 83.3 % vs. 92.8 %, P=NS). In-hospital mortality was comparable in both groups (4.2 % vs. 5.0%, P=NS).
Conclusion: Tirofiban administration before transport to direct angioplasty led to similar angiographic results compared to standard treatment with heparin and aspirin alone.
Keywords: direct angioplasty, acute myocardial infarction, GP IIb/IIIa inhibitors, tirofiban.
Published: December 31, 2004 Show citation
V retrospektivní observační studii za období leden-řijen 2003 autoři srovnávají angiografické ukazatele skupiny nemocných, léčených již před transportem k přímé angioplastice (dPCI) inhibitorem destičkových receptorů GP IIb/IIIa tirofibanem (skupina A, 24 nemocných) s ostatními pacienty bez této léčby (skupina B, 210 nemocných). Obě skupiny nemocných jsou srovnatelné z hlediska věku, pohlaví, výskytu léčeného diabetes mellitus a předchozího infarktu myokardu. Doba od začátku bolesti do zahájení PTCA se nelišila (4,4 hod. vs 4,3 hod., P=NS). Rozdíl byl v rozsahu koronární aterosklerózy, nemocní ve skupině léčené inhibitory GP IIb/IIIa měli větší počet nemocných koronárních tepen (1,87 vs 1,24, p < 0,001).
Koronární průtok podle TIMI klasifikace byl před zahájením PCI v obou skupinách srovnatelný (TIMI 0 66,7 % vs. 70,5 %, P=NS). Po provedení koronární intervence bylo dosaženo normálního koronárního průtoku rovněž u srovnatelného počtu nemocných (83,3 % vs. 92,8 %, P=NS). Mortalita obou skupin nemocných se rovněž významně nelišila (4,2 % vs 5,0 %, P=NS).
Závěr: Podání tirofibanu před transportem k přímé angioplastice pro akutní infarkt myokardu nebylo z hlediska angiografických a klinických výsledků přínosné.
TIROFIBAN ADMINISTRATION BEFORE TRANSPORT TO DIRECT ANGIOPLASTY
In a retrospective 9-month study, we evaluated angiographic parameters in patients treated with tirofiban before transport to direct PCI (group A, 24 patients) and in patients with standard treatment with aspirin and heparin alone (group B, 210 patients). Both groups were comparable in age, gender, presence of diabetes mellitus and previous myocardial infarction. Time from onset of chest pain to direct angioplasty was not different (4.4 hrs vs. 4.3 hrs, P=NS). There was no significant difference in TIMI flow before direct angioplasty (TIMI 0 66.7 % vs. 70.5 %, P=NS) nor after this procedure (TIMI 3 83.3 % vs. 92.8 %, P=NS). In-hospital mortality was comparable in both groups (4.2 % vs. 5.0%, P=NS).
Conclusion
Tirofiban administration before transport to direct angioplasty led to similar angiographic results compared to standard treatment with heparin and aspirin alone.
Download citation
References
- Montalescot G, Barragan P, Wittenberg O. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903.
Go to original source... 
Go to PubMed... - Collet JP, Montalescot G, Lesty C. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation 2001; 103: 2328-34. Go to original source... Go to PubMed...
- Makkar R, Goff B, Eigler N. Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study. Catheter Cardiovasc Interv 1999; 48: 430-4. Go to original source...
- van den Merkhof LF, Zijlstra F, Olsson H. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999; 33: 1528-32. Go to original source... Go to PubMed...
- Lee DP, Herity NA, Hiáty BL. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation 2003; 107: 1497-1501. Go to original source... Go to PubMed...
- Cutlip DE, Ricciardi MJ, Ling FS. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol 2003; 92: 977-80. Go to original source... Go to PubMed...
- Kong DF, Hasselblad V, Harrington RA. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 2003; 92: 651-5. Go to original source... Go to PubMed...
- Batchelor WB, Tolleson TR, Huang Y. Randomized comparison of platelet inhibition with abciximab, tirofiban and eptifibatide durign percuatenous coronary intervention in acute coronary syndromes: the COMPARE trial. Circulation 2002; 106: 1470-6. Go to original source... Go to PubMed...
- Danzi GB, Capuano C, Sesana M. Preliminary experience with a high bolus dose of tirofiban during percutaneous coronary intervention. Curr Med Res Opin 2003; 19: 28-33. Go to original source... Go to PubMed...